Soaring Demand Set to Propel Liver Cirrhosis Market to $2.68 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Liver Cirrhosis Market Through 2025?
The overall valuation of the liver cirrhosis market has witnessed considerable upward momentum recently, projected to advance from a figure of $1.86 billion in 2024 to $1.99 billion in the subsequent year, reflecting a consistent annual expansion rate, or CAGR, of 7.0%; this expansion over the past period is fundamentally linked to several key factors, namely the rising incidence of hepatic ailments, elevated levels of alcohol consumption globally, an advancing average age of the populace, greater outlays on medical care, and the proliferation of supportive governmental programs.

What's the Projected Size of the Global Liver Cirrhosis Market by 2029?
Anticipation is high for substantial expansion within the liver cirrhosis market over the approaching years, projected to reach a valuation of $2.68 billion by 2029, fueled by a compound annual growth rate (CAGR) of 7.7%; this upward trajectory is underpinned by several factors, notably the escalating frequency of hepatitis infections, concurrent with increasing economic prosperity, heightened levels of urbanization, shifts in societal lifestyles, and the expansion of medical tourism, while key developments poised to shape this era involve sophisticated progress in diagnostic instruments, technological breakthroughs, the formation of cooperative ventures and alliances, the incorporation of artificial intelligence methodologies, and the adoption of comprehensive, holistic treatment approaches.

View the full report here:
https://www.thebusinessresearchcompany.com/report/liver-cirrhosis-global-market-report

Top Growth Drivers in the Liver Cirrhosis Industry: What's Accelerating the Market?
A rise in the consumption of alcoholic substances is projected to be the catalyst pushing the liver cirrhosis market toward expansion in the future. Alcohol consumption, defined as the ingestion of drinks containing alcohol, is usually quantified by both volume and how often it occurs. A greater number of individuals are turning to alcohol as a means to alleviate the pressures of everyday life, facilitate social bonding during assemblies, and amplify periods of ease; additionally, its widespread endorsement via various media outlets and its heightened availability in numerous environments contribute to this trend. Treatment protocols for liver cirrhosis in those who consume alcohol excessively concentrate on mitigating liver injury through complete cessation, pharmaceuticals, and ancillary assistance, alongside tackling alcohol dependency via therapeutic interventions and recovery programs. To illustrate this trend, data collected by the National Drugs Library, an organization situated in Ireland specializing in data aggregation, indicated in March 2023 that by 2022, the average intake of alcohol among persons aged fifteen and above amounted to 10.2 liters of absolute alcohol per individual, marking a 7.6 percent escalation compared to the figures from 2021. Consequently, this upward trajectory in alcohol use directly fuels the expansion of the liver cirrhosis market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=22040&type=smp

What Trends Will Shape the Liver Cirrhosis Market Through 2029 and Beyond?
Leading enterprises within the liver cirrhosis sector are concentrating efforts on enhancing therapeutic modalities, notably through the creation of active implantable medical devices, aiming to boost recovery rates and broaden the scope of available treatments. These devices are characterized as electronically powered implants engineered to track, sustain, or better the operations of internal organs. A significant development occurred in December 2024 when the U.S. FDA granted clearance to Sequana Medical NV, a firm located in Belgium, for their alfapump system, establishing it as the inaugural active implantable medical device authorized in the U.S. for addressing the issue of recurring or treatment-resistant ascites stemming from liver cirrhosis. This pioneering technology provides an automated, ongoing method for fluid regulation by channeling surplus abdominal fluid into the bladder, thereby substantially lessening reliance on methods involving physically draining the fluid, known as therapeutic paracentesis. The alfapump signifies a crucial step forward in elevating the quality of life and results for patients, covering a potential market size estimated at around 70,000 individuals in the United States.

What Are the Main Segments in the Liver Cirrhosis Market?
The liver cirrhosismarket covered in this report is segmented -

1) By Type: Alcoholic Cirrhosis; Atrophic Cirrhosis; Biliary Cirrhosis; Cardiac Cirrhosis; Cryptogenic Cirrhosis
2) By Treatment: Antibiotics; Immunosuppressants; Other Treatments
3) By End Users: Hospitals; Specialty Clinics; Ambulatory Surgical Centers; Academic And Research Institutes; Other End Users

Subsegments:

1) By Alcoholic Cirrhosis: Compensated Alcoholic Cirrhosis; Decompensated Alcoholic Cirrhosis; Alcoholic Steatohepatitis (ASH)-Associated Cirrhosis
2) By Atrophic Cirrhosis: Post-necrotic Atrophic Cirrhosis; Macronodular Atrophic Cirrhosis; Micronodular Atrophic Cirrhosis
3) By Biliary Cirrhosis: Primary Biliary Cirrhosis (PBC); Secondary Biliary Cirrhosis; Autoimmune Biliary Cirrhosis
4) By Cardiac Cirrhosis: Right Heart Failure-Induced Cirrhosis; Chronic Passive Congestion Cirrhosis; Ischemic Hepatitis Cirrhosis
5) By Cryptogenic Cirrhosis: Non-Alcoholic Steatohepatitis (NASH)-Associated Cirrhosis; Idiopathic Cirrhosis; Metabolic Syndrome-Associated Cirrhosis

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=22040&type=smp

Which Top Companies are Driving Growth in the Liver Cirrhosis Market?
Major companies operating in the liver cirrhosis market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, Abbott Laboratories, Novartis AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Novo Nordisk A/S, Viatris Inc., Grifols Therapeutics LLC, Shionogi Inc., Galectin Therapeutics Inc., NGM Biopharmaceuticals Inc., Madrigal Pharmaceuticals Inc., Akero Therapeutics Inc.

Which Regions Will Dominate the Liver Cirrhosis Market Through 2029?
North America was the largest region in the liver cirrhosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the liver cirrhosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22040

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.